Modalis gains foundational CRISPR IP access
Modalis Therapeutics has licensed intellectual property (IP) from CRISPR-related gene-editing company Editas Medicine. Read More
Serimmune, Merck reach drug discovery milestone
Serimmune has used its immune mapping technology on clinical and preclinical samples provided by Merck. Read More
CAS offers open-access chemical database for COVID-19
The Chemical Abstracts Service (CAS), a division of the American Chemical Society, announced it has released an open-access database of chemical compounds with known or potential antiviral properties to assist organizations with COVID‑19 research. Read More
GE BioPharma sale to Danaher is complete
The divestment of GE's BioPharma business unit to Danaher is complete, according to an announcement by both companies on March 31. Read More
Viscient to bioprint lung tissues to accelerate COVID-19 research
Biotherapeutics company Viscient Biosciences said it, or a sister company to be funded and launched shortly using the same technology, will use 3D bioprinting technology to create lung tissue to support viral infectivity research and search for an effective therapy against SARS-CoV-2, the novel coronavirus which causes COVID-19. Read More
Bruker launches plethora of new products online
Bruker is showcasing a number of its new analytical systems and other products for biopharma and forensics applications. The products include a new gas analyzer as well as a benchtop x-ray elemental analyzer. Read More
Kleo, Green Cross collaborate on COVID-19 NK combination therapy
Kleo Pharmaceuticals is joining forces with Green Cross LabCell of South Korea to advance testing of natural killer (NK) cell therapies as a potential treatment for COVID-19 patients. Read More
Agilent unveils new handheld raw material ID system
Agilent Technologies has launched Vaya Raman, a handheld raw material identity verification system for pharmaceutical manufacturers. Read More
Generation Bio, Vir partner for mAbs against COVID-9
Generation Bio and Vir Biotechnology have agreed to collaborate on research into the use of monoclonal antibodies against the SARS-CoV-2 virus that causes COVID-19. Read More
J&J seeks to release COVID-19 vaccine by 2021
Johnson & Johnson has selected a lead COVID-19 vaccine candidate from a number of options it has been working on since January. The company hopes to release a vaccine by 2021. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter